DDInter366 DDInter1840
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Chlorzoxazone {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Chlorzoxazone {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Chlorzoxazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Chlorzoxazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Clemastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Chlorzoxazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Cetirizine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Chlorzoxazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepyramine
Mepyramine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Chlorzoxazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Chlorzoxazone {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Chlorzoxazone {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Chlorzoxazone {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Chlorzoxazone (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)
Chlorzoxazone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Trabectedin (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Trabectedin (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Trabectedin (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Chlorzoxazone may lead to a major life threatening interaction when taken with Morphine and Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Chlorzoxazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Chlorzoxazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)